Navigation Links
Harwood Feffer LLP Announces Investigation of OvaScience, Inc.
Date:9/17/2013

NEW YORK, Sept. 17, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On September 10, 2013, the Company disclosed that it was suspending enrollment in connection with its proprietary technology, Augment, in the U.S. after receiving an "untitled" letter from the FDA "questioning the status of Augment… and advising the Company to file an Investigational New Drug (IND) application."     

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own OvaScience shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                         (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
2. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
3. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
4. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. Celtaxsys Announces Successful Completion of Phase 1 Clinical Trial for Development of CTX-4430
8. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
9. Plastic Surgeon Dr. Marc J. Salzman Announces Use of Astanza Trinity Laser Tattoo Removal System, Runs Limited-Time Promotion
10. Sam Solakyan announces Paramount Management Services is now a full-scale MSO
11. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
(Date:3/27/2017)... FRANCISCO , March 27, 2017 ... expected to reach USD 16.0 billion by 2025, according ... The growing prevalence of chronic diseases is anticipated to ... chemistry analyzers, which thereby widens the scope for growth ... geriatric and bariatric population, which is highly susceptible to ...
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... more patients desire to achieve the “perfect smile.” The National Association of Dental ... well as what dentists should be aware of when utilizing dental laboratories and ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment ... City March 13-16, was a busy spot this year. Liz Solovay and Adrian ... for preventing outbreaks among camp communities during the upcoming 2017 camping season. “Lice ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Thank you ... Diego on February 8-10. , This event was exclusive to providers and offered ... , The meeting took place at the Manchester Grand Hyatt where attendees gathered for ...
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
Breaking Medicine News(10 mins):